The evolving HCC treatment landscape: a case study approach
Information
In this workshop, a panel of experts will present case studies depicting their clinical experiences of treating uHCC patients with LENVIMA® monotherapy. This workshop-style session will include discussions around treatment selection, response to treatment and the place for LENVIMA® monotherapy in the future treatment landscape.
DISCLAIMER
The materials for LENVIMA® produced by Eisai for this virtual conference are approved for UK healthcare professionals and other relevant decisions makers. LENVIMA® is indicated in the UK as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
For the full UK prescribing information, go to the following link: eisaihcc.com. Prescribing information may vary depending on local approval for each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Prescribing Characteristics (SPC).
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for the MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events should also be reported to Eisai Ltd on +44(0)845 676 1400/ +44(0)208 600 1400 or EUmedinfo@eisai.net.